iNtRON Biotechnology Inc
048530
Company Profile
Business description
iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.
Contact
137, Sagimakgol-ro, Jungwon-gu
Gyeonggi-do
Seongnam-si
KORT: +82 317395678
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,203.36 | 32.35 | -0.39% |
| DAX 40 | 24,220.56 | 50.31 | -0.21% |
| Dow JONES (US) | 49,527.09 | 377.71 | 0.77% |
| FTSE 100 | 10,486.57 | 11.52 | -0.11% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,426.86 | 166.89 | 0.69% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,109.69 | 45.68 | 0.65% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |